Separation of terbium-161 from gadolinium target irradiated in nuclear reactor

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21340%2F22%3A00361851" target="_blank" >RIV/68407700:21340/22:00361851 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Separation of terbium-161 from gadolinium target irradiated in nuclear reactor
Original language description
Terbium-161 is one of the perspective radionuclides with a potential use in nuclear medicine thanks to its ideal energy of beta radiation and half-life. In addition, it also emits a significant amount of conversion and Auger electrons, which increases its potential therapeutic efficacy. Terbium-161 can be prepared as no carrier added by neutron irradiation of highly enriched gadolinium-160 target in a nuclear reactor. After irradiation, it is necessary to separate terbium from the target. In this work, several irradiations of highly enriched Gd-160 target in the form of oxide or nitrate were performed in the nuclear reactor LVR 15 (CV Řež). For separation of Tb-161 from target, cation exchange chromatography on Dowex 50Wx8 (H+), 100-200 mesh with variously concentrated alpha-hydroxyisobutyric acid as eluent was used. The fractions containing Tb-161 were purified from alpha-hydroxyisobutyric acid also on the cation exchange resin, using hydrochloric acid as eluent. The purity of sample was verified by gamma spectrometry on an HPGe detector (radionuclide impurities) and by ICP-MS method (stable impurities).
Czech name
—
Czech description
—

Project
<a href="/en/project/TO01000074" target="_blank" >TO01000074: Efficient Low-energy Electron Cancer Therapy with Terbium-161</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)